Eliana Merle
Stock Analyst at UBS
(1.23)
# 1,263
Out of 4,479 analysts
50
Total ratings
37.93%
Success rate
-14.46%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $253 → $288 | $247.61 | +16.31% | 1 | Jun 28, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Downgrades: Neutral | $28 → $5 | $3.57 | +40.06% | 3 | Jun 20, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $51 → $47 | $24.91 | +88.68% | 2 | May 28, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $89 → $85 | $34.98 | +143.00% | 5 | May 8, 2024 | |
| MRNA Moderna | Maintains: Buy | $143 → $151 | $117.07 | +28.98% | 3 | May 7, 2024 | |
| KOD Kodiak Sciences | Maintains: Neutral | $3 → $5 | $2.24 | +123.21% | 3 | Apr 4, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $19 → $18 | $6.72 | +167.86% | 2 | Mar 27, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $110 → $101 | $78.76 | +28.24% | 3 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $337 → $410 | $271.67 | +50.92% | 2 | Mar 15, 2024 | |
| AKRO Akero Therapeutics | Maintains: Buy | $39 → $42 | $22.38 | +87.67% | 3 | Mar 5, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Neutral | $61 → $10 | $2.79 | +258.42% | 1 | Feb 22, 2024 | |
| RVMD Revolution Medicines | Initiates: Buy | $40 | $37.38 | +7.01% | 1 | Dec 20, 2023 | |
| ANAB AnaptysBio | Maintains: Neutral | $28 → $21 | $23.94 | -12.28% | 3 | Nov 2, 2023 | |
| ETNB 89bio | Maintains: Buy | $36 → $25 | $7.60 | +228.95% | 2 | Oct 12, 2023 | |
| QURE uniQure | Maintains: Buy | $45 → $42 | $4.01 | +947.38% | 4 | May 19, 2023 | |
| CVAC CureVac | Upgrades: Buy | $18 | $3.34 | +438.92% | 1 | Jan 19, 2023 | |
| GOSS Gossamer Bio | Maintains: Buy | $19 → $8 | $0.96 | +733.51% | 2 | Dec 7, 2022 | |
| GLUE Monte Rosa Therapeutics | Initiates: Buy | $22 | $3.59 | +512.81% | 1 | Oct 13, 2022 | |
| RGNX REGENXBIO | Maintains: Buy | $51 → $47 | $10.75 | +337.21% | 1 | Jun 23, 2022 | |
| FOLD Amicus Therapeutics | Initiates: Buy | n/a | $9.85 | - | 2 | May 21, 2021 | |
| KYMR Kymera Therapeutics | Initiates: Buy | n/a | $30.22 | - | 1 | May 21, 2021 | |
| ARVN Arvinas | Initiates: Buy | n/a | $24.85 | - | 2 | May 21, 2021 | |
| GLPG Galapagos NV | Maintains: Neutral | n/a | $25.34 | - | 2 | Aug 19, 2020 |
Alnylam Pharmaceuticals
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $247.61
Upside: +16.31%
Zentalis Pharmaceuticals
Jun 20, 2024
Downgrades: Neutral
Price Target: $28 → $5
Current: $3.57
Upside: +40.06%
BridgeBio Pharma
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $24.91
Upside: +88.68%
Apellis Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $89 → $85
Current: $34.98
Upside: +143.00%
Moderna
May 7, 2024
Maintains: Buy
Price Target: $143 → $151
Current: $117.07
Upside: +28.98%
Kodiak Sciences
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $2.24
Upside: +123.21%
Terns Pharmaceuticals
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $6.72
Upside: +167.86%
BioNTech SE
Mar 27, 2024
Maintains: Neutral
Price Target: $110 → $101
Current: $78.76
Upside: +28.24%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $337 → $410
Current: $271.67
Upside: +50.92%
Akero Therapeutics
Mar 5, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $22.38
Upside: +87.67%
RAPT Therapeutics
Feb 22, 2024
Downgrades: Neutral
Price Target: $61 → $10
Current: $2.79
Upside: +258.42%
Revolution Medicines
Dec 20, 2023
Initiates: Buy
Price Target: $40
Current: $37.38
Upside: +7.01%
AnaptysBio
Nov 2, 2023
Maintains: Neutral
Price Target: $28 → $21
Current: $23.94
Upside: -12.28%
89bio
Oct 12, 2023
Maintains: Buy
Price Target: $36 → $25
Current: $7.60
Upside: +228.95%
uniQure
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $4.01
Upside: +947.38%
CureVac
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $3.34
Upside: +438.92%
Gossamer Bio
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $0.96
Upside: +733.51%
Monte Rosa Therapeutics
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $3.59
Upside: +512.81%
REGENXBIO
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $10.75
Upside: +337.21%
Amicus Therapeutics
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $9.85
Upside: -
Kymera Therapeutics
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $30.22
Upside: -
Arvinas
May 21, 2021
Initiates: Buy
Price Target: n/a
Current: $24.85
Upside: -
Galapagos NV
Aug 19, 2020
Maintains: Neutral
Price Target: n/a
Current: $25.34
Upside: -